C-Series

ProdromeNeuro™ Improves Oxidative Stress Biomarkers in Cognitively Impaired Persons (C106)

Supplementation with ProdromeNeuro was observed to elevate blood DHA-plasmalogen levels. The increase in blood DHA-plasmalogens correlated with a decrease in malondialdehyde levels (r=-0.5, p=7.2e-07) and an increase in catalase activity (r=0.28, p=0.008). Superoxide dismutase activity was increased in persons with low baseline activity (p=0.017).  To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for …

ProdromeNeuro™ Improves Oxidative Stress Biomarkers in Cognitively Impaired Persons (C106) Read More »

ProdromeNeuro™ Improves Cognition and Mobility in Cognitively Impaired Persons (C105)

Supplementation with ProdromeNeuro was observed to elevate DHA-plasmalogens in a dose-dependent manner and to improve cognition (p=1.8e-02) and mobility (p=2.9e-05) in persons diagnosed with mild to moderate dementia.  To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C105, Supplements (Series C). ProdromeNeuro is a plasmalogen supplement designed to specifically elevate DHA plasmalogen levels. An escalating dose study was …

ProdromeNeuro™ Improves Cognition and Mobility in Cognitively Impaired Persons (C105) Read More »

Plasmalogen Supplementation Prevents Demyelination (C104)

Animals pretreated with plasmalogen supplements are protected against the neurotoxin cuprizone. Cuprizone selectively targets oligodendrocytes and creates symptoms and neuropathology similar to multiple sclerosis. To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C104, Supplements (Series C). Multiple sclerosis (MS) is a neurodegenerative disease that affects a specific …

Plasmalogen Supplementation Prevents Demyelination (C104) Read More »

Plasmalogen Supplementation Prevents Neurodegeneration (C103)

Animals pretreated with plasmalogen supplements are protected against the neurotoxin MPTP. MPTP selectively targets dopamine neurons and creates symptoms and neuropathology similar to Parkinson’s disease.   To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C103, Supplements (Series C). Parkinson’s disease is a neurodegenerative disease that affects …

Plasmalogen Supplementation Prevents Neurodegeneration (C103) Read More »

The Three Main Functions of Plasmalogens (C102)

Plasmalogens neutralize peroxides, they modulate membrane structure and the function of membrane proteins, and they modulate the efficiency and ease of vesicular release of neurotransmitters. They are obligate to life.    To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C102, Supplements (Series C). Plasmalogens are a type of glycerophospholipid. Glycerophospholipids are …

The Three Main Functions of Plasmalogens (C102) Read More »

Plasmalogen Precursor Design and Development (C101)

Dr. Goodenowe was the first to discover and patent that low blood plasmalogens caused Alzheimer’s and he was the first to design and patent plasmalogen supplements that are effective neuroprotectants.     To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for seminar C101, Supplements (Series C). The plasmalogen story began in 2005 when I initially sourced …

Plasmalogen Precursor Design and Development (C101) Read More »